Home > PJ (current issue) > The Society / News Centre

The Pharmaceutical Journal
Vol 274 No 7337 p218
19 February 2005


Society summary

Statutory Committee

Superintendent had poor English and little grasp of his responsibilities more

Restoration application adjourned for third time pending findings of an MHRA investigation more


Superintendent had poor English and little grasp of his responsibilities

The Statutory Committee has reprimanded a pharmacist whose problems with the English language and poor grasp of his professional responsibilities had led to a large number of errors and bad practices while he was acting as a superintendent pharmacist.

The reprimand was conditional upon him undertaking to bring his English up to an acceptable level as soon as possible and not practising as a superintendent for at least three years, and then only on the written advice of a Society inspector.

The inquiry concerned Gholamreza Youseffi, of Flat 33, Risborough House, 1 Mallory Street, London NW8, and Sumer Health Ltd, which owns Sumer Pharmacy, 340–342 Harrow Road, London W9. The committee also reprimanded the company. The inquiry arose from a complaint by the Council of the Royal Pharmaceutical Society, that Mr Youseffi had demonstrated a failure to understand the responsibilities of a superintendent pharmacist and of a pharmacist providing professional services and/or to discharge them in the following respects:

· the responsibility to ensure the observance of all legal and professional requirements in relation to the pharmaceutical aspects of the business
· the responsibility to ensure that all staff are informed of the professional activities they are expected to undertake
· the responsibility to ensure that working conditions, facilities, equipment and materials enable the provision of services to professionally accepted standards
· the responsibility to ensure that pharmacists and other staff employed by them are sufficiently competent in English
· the requirement of professional competence that pharmacists should be ready and able to provide information and advice about any medicine supplied by them or under their authority and that, when giving advice to prescribers, patients and others, they must be able to demonstrate competence and knowledge of medicines within the relevant therapeutic class.

When the inquiry opened on Tuesday 21 September 2004, the committee heard that Mr Youseffi registered with the Society on 9 July 2001 and was appointed superintendent pharmacist of Sumer Health Ltd on 5 August 2002.

It was alleged that when one of the Society’s inspectors visited the pharmacy on 14 August 2003, she found that Mr Youseffi seemed to have difficulty understanding spoken English and had difficulty understanding a questionnaire that she had sent in advance of her visit. It was also alleged that when another inspector visited the pharmacy in the guise of a member of the public on 15 August 2003, Mr Youseffi had difficulty in communicating clearly with her too.

During interviews with one of the inspectors on 5 September and 8 October 2003 Mr Youseffi had required the services of an Italian interpreter. He admitted that when he had accepted appointment as superintendent pharmacist he was not sufficiently competent in the understanding and use of the English language. He also admitted that since registering with the Society he had failed to undertake any activities specifically designed to improve his competence in English.

He further admitted that when he accepted his appointment as superintendent pharmacist he did not have a complete understanding of the responsibilities of a superintendent as set out in ‘Medicines, ethics and practice: a guide for pharmacists’. He also stated that he was not able to accept greater responsibilities than checking prescriptions.

Mr Youseffi also admitted a number of specific failings, including record-keeping and other errors relating to the supply of Controlled Drugs, record-keeping and other errors relating to the supply of emergency hormonal contraception, allowing the sale of a pharmacy medicine (a topical steroid product) in an inappropriate manner, a failure to have addressed concerns raised by the local inspector two months before her 14 August visit, a failure to ensure that staff were sufficiently competent in English and the supply of an inappropriate product and incorrect advice in response to a request for malaria prophylaxis.

Giving the committee’s decision on 21 September 2004, the chairman, Lord Fraser of Carmyllie, QC, said that the Council found the misconduct by Mr Youseffi proved and such as to render him unfit to be on the Register. However, if satisfactory conditions could be settled, the committee would restrict its sanction to a reprimand. It would adjourn the inquiry for one month to give Mr Youseffi and his advisers time to draw up an undertaking in relation to his future practice. In the intervening period, the only term the committee would imply was that Mr Youseffi should not act as a superintendent pharmacist.

Reprimanding the company, the chairman said that the committee would not order the disqualification of its premises because it now had a superintendent pharmacist in place who clearly understood what was required.

When the inquiry resumed on 19 October 2004, the chairman added that the committee wanted to be confident not just that Mr Youseffi had sufficient English to enable him to discharge the responsibilities of a superintendent pharmacist at some time in the future, but also that as soon as possible he understood sufficient English to enable him to communicate with members of the public.

The chairman said: “We are concerned with the public interest, the public safety, that Mr Youseffi truly understands what a member of the public might be saying to him and also that he would be able to communicate back.”

The committee gave its approval to the wording of an undertaking by Mr Youseffi that included a requirement that he should reach Level 6 of the International English Language Testing System at the earliest possible date and certainly within three years.

The chairman said that, in those circumstances, the committee would conclude the case by restricting its sanction to that of a reprimand.

Back to Top


Restoration application adjourned for third time pending findings of an MHRA investigation

An application for restoration to the register by Rajandra Gulubchand Shah, of 120 Golders Green Road, London NW11, has been adjourned for a third time by the Statutory Committee pending the result of an investigation by the Medicines and Healthcare products Regulatory Agency.

The committee had order the removal of Mr Shah’s name at a three-day hearing on 26, 27 and 28 February 2002. The removal took effect on 27 May 2002. Mr Shah had sold Viagra without a prescription to a Sunday People journalist and had failed to ensure that accurate records were kept of Viagra transactions (PJ, 7 December 2002, p829).

Mr Shah’s application for restoration was first heard on 26 January 2004. The committee decided that he was “well on his way to learning his lesson” but, because it would not consider restoration in less than two years other than in exceptional circumstances, it postponed its decision until after 27 May 2004.

The application was heard again on 21 June, when the committee learnt that in October 2003 Mr Shah had been interviewed by the MHRA in connection with counterfeit Viagra tablets, a fact that he had failed to disclose to the committee at the January 2004 hearing. The case was adjourned for a further three months (PJ, 11 September, p365).

When the hearing resumed on 20 September 2004, the committee heard that the MHRA was still continuing with an investigation into Mr Shah and a number of other people in connection with the alleged sale of counterfeit Viagra to a company in the Bahamas. The investigator had indicated that within three months it would be clearer what action, if any, would be taken in respect of those matters.

The chairman, Lord Fraser of Carmyllie, QC, said that it was difficult to proceed when there was a possibility of criminal proceedings. The inquiry would therefore be adjourned for a further three months.

Back to Top


©The Pharmaceutical Journal